Principal Financial Group Inc. Lowers Stock Position in Cellectis S.A. (NASDAQ:CLLS)

Principal Financial Group Inc. reduced its stake in Cellectis S.A. (NASDAQ:CLLS) by 5.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 411,800 shares of the biotechnology company’s stock after selling 25,200 shares during the quarter. Principal Financial Group Inc. owned 0.74% of Cellectis worth $881,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in CLLS. XTX Topco Ltd purchased a new stake in Cellectis in the second quarter valued at approximately $29,000. Long Focus Capital Management LLC raised its holdings in shares of Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after buying an additional 130,000 shares during the period. Finally, First Affirmative Financial Network acquired a new position in Cellectis during the 3rd quarter worth about $45,000. 63.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CLLS has been the subject of several research reports. Barclays dropped their target price on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. StockNews.com initiated coverage on shares of Cellectis in a research note on Thursday. They set a “sell” rating on the stock.

Cellectis Price Performance

Shares of NASDAQ CLLS opened at $1.87 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78. The company has a market cap of $103.93 million, a price-to-earnings ratio of -1.44 and a beta of 3.10. The stock’s 50-day moving average is $1.97 and its two-hundred day moving average is $2.20. Cellectis S.A. has a 1-year low of $1.70 and a 1-year high of $3.77.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The company had revenue of $18.05 million for the quarter, compared to analyst estimates of $5.00 million. During the same period in the prior year, the firm posted ($0.31) earnings per share. Analysts forecast that Cellectis S.A. will post -0.46 EPS for the current fiscal year.

Cellectis Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.